Johnson & Johnson’s Darzalex and Spravato Achieve Milestones: Darzalex Leads Sales, Spravato Surpasses $1 Billion Revenue

Darzalex Sales Performance:

Darzalex, a multiple myeloma drug, has become Johnson & Johnson's top seller, with sales approaching $10 billion in 20231.
The drug has shown a 22% increase in sales from the second quarter of the previous year, reaching $2.43 billion in one quarter1.

Spravato Revenue Milestone:

Spravato, a depression drug, has crossed $1 billion in revenue for the first time in 2024, marking a 56% increase from 20235.
The drug's sales accelerated in the second quarter of 2024, totaling $271 million between April and June, a 61% increase from the same period in the previous year2.

Market Impact and Future Projections:

Johnson & Johnson has boosted its annual sales guidance by approximately $1 billion to a range of $98.8 billion to $99.8 billion, partly due to Darzalex's strong performance1.
The company expects to enhance its position in the multiple myeloma market with new products like Tecvayli and Carvykti, aiming to have three out of every four patients starting on a Janssen regimen by the end of the decade1.
Spravato's success supports the commercial viability of psychedelic drugs for mental health, with potential implications for other companies developing similar treatments2.

Sources:

1. https://www.fiercepharma.com/pharma/johnson-johnsons-darzalex-continues-its-upward-trajectory-company-boosts-2023-revenue

2. https://finance.yahoo.com/news/strengthening-spravato-sales-positive-sign-150000573.html?guccounter=1

5. https://endpts.com/jjs-spravato-hit-1b-in-revenue-in-2024/